Literature DB >> 18370830

Nonalcoholic steatohepatitis and the metabolic syndrome.

Joy Jiang1, Natalie Torok.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a major form of chronic liver disease in adults and children. It is one of the consequences of the current obesity epidemic, and can progress to nonalcoholic steatohepatitis (NASH), characterized by steatosis, inflammation, and progressive fibrosis, ultimately leading to cirrhosis and end-stage liver disease. The factors implicated in this progression are poorly understood. NASH is closely associated with obesity and the metabolic syndrome. Recent studies emphasize the role of insulin resistance, oxidative stress, lipid peroxidation, and cytokine release in the development of NASH. This review summarizes the current knowledge on the etiology and pathomechanism of NASH and the role of the metabolic syndrome in NASH development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18370830     DOI: 10.1089/met.2007.0026

Source DB:  PubMed          Journal:  Metab Syndr Relat Disord        ISSN: 1540-4196            Impact factor:   1.894


  16 in total

Review 1.  The metabolic syndrome.

Authors:  Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel
Journal:  Endocr Rev       Date:  2008-10-29       Impact factor: 19.871

2.  High-frequency ultrasound imaging for longitudinal evaluation of non-alcoholic fatty liver disease progression in mice.

Authors:  Itziar Fernández-Domínguez; J Javier Echevarria-Uraga; Nieves Gómez; Zigmund Luka; Conrad Wagner; Shelly C Lu; José M Mato; Maria L Martínez-Chantar; Juan Rodríguez-Cuesta
Journal:  Ultrasound Med Biol       Date:  2011-06-08       Impact factor: 2.998

3.  Hepatic steatosis causes induction of the chemokine RANTES in the absence of significant hepatic inflammation.

Authors:  Georgi Kirovski; Erwin Gäbele; Christoph Dorn; Lukas Moleda; Christoph Niessen; Thomas S Weiss; Hella Wobser; Doris Schacherer; Christa Buechler; Hermann E Wasmuth; Claus Hellerbrand
Journal:  Int J Clin Exp Pathol       Date:  2010-08-02

4.  Cathepsin B deficiency ameliorates liver lipid deposition, inflammatory cell infiltration, and fibrosis after diet-induced nonalcoholic steatohepatitis.

Authors:  Wenqian Fang; Zhiyong Deng; Feriel Benadjaoud; Chongzhe Yang; Guo-Ping Shi
Journal:  Transl Res       Date:  2020-05-11       Impact factor: 7.012

5.  Diabetes mellitus, and not obesity, is associated with lower survival following liver transplantation.

Authors:  Robert J Wong; Ramsey Cheung; Ryan B Perumpail; Edward W Holt; Aijaz Ahmed
Journal:  Dig Dis Sci       Date:  2015-01-18       Impact factor: 3.199

6.  A Mouse Model of Metabolic Syndrome: Insulin Resistance, Fatty Liver and Non-Alcoholic Fatty Pancreas Disease (NAFPD) in C57BL/6 Mice Fed a High Fat Diet.

Authors:  Julio C Fraulob; Rebeca Ogg-Diamantino; Caroline Fernandes-Santos; Marcia Barbosa Aguila; Carlos A Mandarim-de-Lacerda
Journal:  J Clin Biochem Nutr       Date:  2010-04-10       Impact factor: 3.114

7.  Preventive effects of chronic exogenous growth hormone levels on diet-induced hepatic steatosis in rats.

Authors:  Ying Qin; Ya-ping Tian
Journal:  Lipids Health Dis       Date:  2010-07-26       Impact factor: 3.876

8.  The development of a metabolic disease phenotype in CTP:phosphoethanolamine cytidylyltransferase-deficient mice.

Authors:  Morgan D Fullerton; Fatima Hakimuddin; Arend Bonen; Marica Bakovic
Journal:  J Biol Chem       Date:  2009-07-22       Impact factor: 5.157

Review 9.  Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis.

Authors:  Yusuf Yilmaz; Alla Eldeen Kedrah; Osman Ozdogan
Journal:  World J Gastroenterol       Date:  2009-09-21       Impact factor: 5.742

10.  Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease.

Authors:  Hai-Ning Wang; Yan-Rong Wang; Guo-Qiang Liu; Zhe Liu; Pei-Xian Wu; Xiao-Ling Wei; Tian-Pei Hong
Journal:  World J Gastroenterol       Date:  2008-12-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.